

# Palladium-Catalyzed Ortho-Alkoxylation of *N*-Benzoyl $\alpha$ -Amino Acid Derivatives at Room Temperature


Shuangjie Li,<sup>†</sup> Wei Zhu,<sup>‡</sup> Feng Gao,<sup>‡</sup> Chunpu Li,<sup>‡</sup> Jiang Wang,<sup>‡</sup> and Hong Liu<sup>\*,‡</sup>

<sup>†</sup>School of Pharmacy, China Pharmaceutical University, Jiangsu Nanjing 210009, P. R. China

<sup>‡</sup>Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, P. R. China

**S** Supporting Information

**ABSTRACT:** An efficient palladium-catalyzed ortho-alkoxylation of *N*-benzoyl  $\alpha$ -amino acid derivatives at room temperature has been explored. This novel transformation, using amino acids as directing groups, Pd(OAc)<sub>2</sub> as catalyst, alcohols as the alkoxylation reagents, and PhI(OAc)<sub>2</sub> as the oxidant, showed wide generality, good functional tolerance, and high monoselectivity and regioselectivity.



## INTRODUCTION

Functionalized amino acid derivatives representing an important class of privileged structures have been widely found in numerous biologically active compounds and natural products (Figure 1).<sup>1</sup> Among them, *o*-alkoxyl-substituted *N*-benzoyl  $\alpha$ -amino acid derivatives serve as useful intermediates in drug discovery and medicinal chemistry.<sup>2</sup> The construction of such scaffolds is mainly achieved by Ullmann reaction, while traditional methods often suffer from harsh reaction conditions, prefunctionalization of substrates, and limited generality.<sup>3</sup> Thus, there remains the need to develop efficient and economical methodologies for elaborating amino acid derivatives under mild conditions.

In past decades, selective C–H functionalization, assisted by directing groups, has drawn considerable attention and emerged as a powerful tool to construct C–C or C–X bonds.<sup>4</sup> Very recently, environmentally friendly and inexpensive amino acid moieties have been employed as novel directing groups in C–H activation for the modification of amino acid derivatives (Scheme 1A).<sup>5</sup> The special structure of amino acid made itself as a feasible directing group without the necessary of being removed and the products are very useful building blocks for making bioactive molecules.

Despite the great progress that has been achieved with Pd-catalyzed direct ortho-alkoxylation of C(sp<sup>2</sup>)–H bonds,<sup>6</sup> huge challenges still remain in the development of environmentally friendly and efficient transformation systems for the selective monoalkoxylation of C–H bonds under mild conditions. Given the importance of  $\alpha$ -amino acid derivatives, we herein report the palladium-catalyzed alkoxylation of *N*-benzoyl  $\alpha$ -amino acid derivatives at room temperature (Scheme 1B).

## RESULTS AND DISCUSSION

To verify our hypothesis, we initiated investigation of the direct ortho-methoxylation of *N*-benzoyl  $\alpha$ -amino acid **1a**. After extensive attempts, 2-(2-methoxybenzamido)-2-methylpropanoic acid **2a** was afforded in 29% yield with Pd(OAc)<sub>2</sub> as catalyst and DMP as oxidant at room temperature (Table 1, entry 1). As shown in Table 1, various oxidants, palladium catalysts, and solvents were screened for the best reaction conditions. The oxidant had a remarkable impact on the reaction yield, and PhI(OAc)<sub>2</sub> gave the best yield (Table 1, entry 4). The effect of different solvents on the transformation was subsequently investigated. Among them, a mixed solvent that included toluene led to a slight increase in yield, while other mixed solvents resulted in a decrease in yield (entries 5–8). Furthermore, choosing toluene as cosolvent is due to solubility. The yield was slightly decreased in the presence of oxygen, which was consistent with earlier findings (entries 10 and 11).<sup>7</sup> Compared with PdCl<sub>2</sub>, Pd(OAc)<sub>2</sub> proved to be the better catalyst (entry 12).

With the optimal conditions in hand, the substrate scope of *N*-benzoyl  $\alpha$ -amino acid derivatives was investigated (Table 2). Generally, various substituents both on the aromatic ring and on  $\alpha$ -amino acid moieties were well tolerated in this direct alkoxylation reaction and afforded the corresponding mono-methoxyl products in moderate to high yields (Table 2). Cyclic amino acid derivatives worked well under standard conditions with high yields (**2b–d**);  $\alpha$ -monosubstituted amino acids derivatives proceeded smoothly with moderate to high yields (**2e–h**), while the glycine derivative gave a slightly lower yield (**2i**). Notably, the chirality of the amino acids substrate was not influenced under this mild transformation condition (**2h**, ee > 99%), guaranteeing further applications.

The influence of different substituents at the aromatic ring was evaluated. To our delight, both electron-rich and electron-poor amino acid derivatives were well tolerated without any dimethoxyl products detected. The protocol was found to be broadly applicable for this type of derivative bearing electron-donating or -withdrawing substituents on the phenyl ring (**2j–**

Received: September 14, 2016

Published: November 21, 2016





Figure 1. Bioactive *o*-alkoxy-substituted derivatives.

### Scheme 1. Palladium-Catalyzed C–H Activation of Amino Acid Derivatives

#### A) Previous Work:



#### B) This Work:





Table 1. Optimization of Reaction Conditions<sup>a</sup>



entry	Pd-cat.	oxidant	solvent	yield (%)
1	Pd(OAc) <sub>2</sub>	DMP	MeOH	29
2	Pd(OAc) <sub>2</sub>	NaIO <sub>3</sub>	MeOH	NR <sup>b</sup>
3	Pd(OAc) <sub>2</sub>	Na <sub>2</sub> S <sub>2</sub> O <sub>8</sub>	MeOH	NR <sup>b</sup>
4	Pd(OAc) <sub>2</sub>	PhI(OAc) <sub>2</sub>	MeOH	83
5	Pd(OAc) <sub>2</sub>	PhI(OAc) <sub>2</sub>	DCE/MeOH(1:1)	85
6	Pd(OAc) <sub>2</sub>	PhI(OAc) <sub>2</sub>	CH <sub>3</sub> CN/MeOH(1:1)	78
7	Pd(OAc) <sub>2</sub>	PhI(OAc) <sub>2</sub>	DMF/MeOH(1:1)	54
8	Pd(OAc) <sub>2</sub>	PhI(OAc) <sub>2</sub>	THF/MeOH(1:1)	NR <sup>b</sup>
9	Pd(OAc) <sub>2</sub>	PhI(OAc) <sub>2</sub>	PhMe/MeOH(1:1)	87
10 <sup>c</sup>	Pd(OAc) <sub>2</sub>	PhI(OAc) <sub>2</sub>	PhMe/MeOH(1:1)	76
11 <sup>d</sup>	Pd(OAc) <sub>2</sub>	PhI(OAc) <sub>2</sub>	PhMe/MeOH(1:1)	78
12	PdCl <sub>2</sub>	PhI(OAc) <sub>2</sub>	PhMe/MeOH(1:1)	65


<sup>a</sup>Unless otherwise specified, all reactions were carried out with 0.2 mmol of **1a**, 0.02 mmol of Pd-cat., and 0.3 mmol of oxidant under argon atmosphere at room temperature for 12 h. All listed yields are isolated ones. <sup>b</sup>NR = no reaction. <sup>c</sup>The reaction were carried out under O<sub>2</sub> atmosphere. <sup>d</sup>The reaction were carried out under air.

p). Moreover, halogens, such as F, Cl, and Br, were well tolerated under the standard reaction conditions (**2m–o**). The broad

functional group tolerance highlights the potential utility of this reaction in the late-stage modification of complex molecules as well as in the total synthesis of natural products. The cleavage of C–H bonds in meta-substituted substrates occurred predominantly at less-hindered sites to give moderate to good yields and excellent regioselectivity, irrespective of the electronic nature of the substituents (**2q** and **2r**). The thiophene substrate also provided the desired products in moderate yield (**2s**). However, substrate 2-(2-methoxybenzamido)-2-methylpropanoic acid did not afford the corresponding product. The alkoxylation reaction did not proceed when the amino acid was protected with higher chain length analogues such phenylacetyl. Importantly, we also carried it out on a gram scale without any additives to afford **2a** in 87% yield (Scheme 2).


Next, we investigated a variety of linear and branched alcohols as coupling partners, which demonstrated wide generality and moderate to high yields. Generally, the primary alcohols, such as ethanol, propanol, 3-trifluoro-1-propanol, and phenylethanol, could be transformed into the corresponding ethers in excellent yields (**3a–d**) (Table 3). The increased steric hindrance from the benzyl alcohol and branched alcohols led to a decrease in yields, while the corresponding products could be afforded in good yields at elevated temperatures (**3e–i**). Unfortunately, the *tert*-butoxy-substituted product could not be achieved under these reaction conditions, which indicated the important influence of the steric effect.

To obtain more insight into the mechanism, some controlled experiments were performed. The addition of 2,2,6,6-tetramethylpiperidine-*N*-oxyl (TEMPO) as a radical quencher slightly inhibited the reaction (Scheme 3, eq 1), suggesting that the reaction does not involve a radical pathway. As shown in Scheme 3, the KIE was observed to be 4.0 (Scheme 3, eq 2), indicating that the C–H bond cleavage at the ortho-position of the *N*-benzoyl  $\alpha$ -amino acid is most likely involved with the rate-limiting step. The carboxyl group of the substrate was crucial to the reaction based on the fact that substrate **1t** or **1u** was not transformed into the corresponding product under the standard reaction conditions (Scheme 3, eq 3). On the basis of previous literature,<sup>6c,7b,8</sup> a plausible mechanism is proposed in Scheme 4. First, the coordination of the nitrogen atom and oxygen atom to the Pd catalyst generates a palladium intermediate (I) followed by concerted metalation–deprotonation (CMD) process to produce the palladacycle complexes II. Cyclopalladated intermediate II is then oxidized to a high-valent Pd intermediate (III) by PhI(OAc)<sub>2</sub>. In the presence of alcohol solvent, the OAc ligands of III could be exchanged to form intermediate IV, which could undergo C–OR RE to give alkoxyated products.

Table 2. Scope of *N*-Benzoyl  $\alpha$ -Amino Acid Derivatives<sup>a</sup>

<sup>a</sup>Unless otherwise specified, all the reactions were carried out with 0.2 mmol of 1, 0.02 mmol of Pd(OAc)<sub>2</sub>, 0.3 mmol of PhI(OAc)<sub>2</sub>, and MeOH/toluene (1:1) as solvent under argon atmosphere at room temperature for 12 h. All listed yields are isolated ones. <sup>b</sup>The reaction was performed at 80 °C. <sup>c</sup>NR = no reaction.

### Scheme 2. Gram-Scale Reaction




### CONCLUSION

We have successfully developed an efficient and environmentally friendly palladium-catalyzed alkoxylation of C(sp<sup>2</sup>)-H bonds in  $\alpha$ -amino acid derivatives at room temperature. This reaction

features broad substrate scopes, good tolerance, and high monoselectivity and regioselectivity. This mild procedure will be of importance to medicinal chemists.


### EXPERIMENTAL SECTION

**General Information.** Unless otherwise noted, the reagents (chemicals) were purchased from commercial sources and used without further purification. Water was deionized before use. Analytical thin layer chromatography (TLC) was HSGF 254 (0.15–0.2 mm thickness). Compound spots were visualized by UV light (254 nm). Column chromatography was performed on silica gel FCP 200–300. NMR spectra were run on a 400 or 500 MHz instrument. Chemical shifts were reported in parts per million (ppm,  $\delta$ ) downfield from tetramethylsilane. Proton coupling patterns are described as singlet (s), doublet (d), triplet

Table 3. Scope of Various Alcohols<sup>a</sup>

<sup>a</sup>Unless otherwise specified, all the reactions were carried out with 0.2 mmol of **1**, 0.02 mmol of Pd(OAc)<sub>2</sub>, 0.3 mmol of PhI(OAc)<sub>2</sub>, and ROH/toluene (1:1) under argon atmosphere at room temperature for 12 h. All listed yields are isolated ones. <sup>b</sup>The reaction was performed at 80 °C.

## Scheme 3. Control Experiments




(t), quartet (q), multiplet (m), and broad (br). Low- and high-resolution mass spectra (LRMS and HRMS) were measured on a spectrometer.

**General Procedure for the Synthesis of Substrates 1a–5.** 2-Amino-2-methylpropionic acid (2 g, 19.4 mmol) was dissolved in 1 M NaOH aqueous solution (20 mL). The mixture was cooled to 0 °C, and then benzoyl chloride (2.30 mL, 19.4 mmol) and 1 M NaOH aqueous solution (20 mL) were added dropwise simultaneously. The resulting mixture was stirred for 5 h at room temperature. Then 1 M HCl (60 mL) was added to the reaction mixture and stirred for 10 min. The resulting solid was collected by filtration and washed with water and Et<sub>2</sub>O. The desired product **1a** was obtained as a white solid (3.02 g, 72%).

Compounds **1b–s** were prepared in a similar manner with different yields (45–70%).

**General Procedure for the Alkylation of Substrates.** Substrate **1** (0.2 mmol), PhI(OAc)<sub>2</sub> (97 mg, 0.3 mmol), Pd(OAc)<sub>2</sub> (4.5 mg, 0.02 mmol), alcohol (1 mL), and toluene (1 mL) were added to a 25 mL tube under argon. The tube was sealed, and the mixture was stirred at room temperature for 12 h. After completion of the reaction, the solution was concentrated in a vacuum. The residue was purified using a silica gel column (DCM/MeOH/HAC = 100:5:1 as eluent) to give the corresponding pure products.

Scheme 4. Plausible Reaction Mechanism



#### Determination of Intermolecular Kinetic Isotope Effect.

Substrate benzoylalanine (**1h**) (0.2 mmol, 19 mg), (benzoyl-2,3,4,5,6- $d_5$ )alanine ( $d_5$ -**1h**) (0.2 mmol, 20 mg),  $\text{PhI}(\text{OAc})_2$  (97 mg, 0.3 mmol),  $\text{Pd}(\text{OAc})_2$  (4.5 mg, 0.02 mmol), methanol (1 mL), and toluene (1 mL) were added to a 25 mL tube under argon. The mixture was stirred at room temperature for 4 h, and the solution was concentrated by vacuum. The residue was purified with a silica gel column (DCM/MeOH/HAc = 100:5:1 as eluent) to give the corresponding pure product. The ratio of  $2h/d_4$ - $2h$  was determined to be 8.00/2.00 (KIE = 4.0) by  $^1\text{H}$  NMR spectroscopy.

**Chiral HPLC Analysis of Products.** Sample A [*rac*-2-benzamidopropanoic acid (prepared under epimerization-free conditions from *rac*-2-aminopropanoic acid)], sample B [D-2-benzamidopropanoic acid (prepared under epimerization-free conditions from D-2-aminopropanoic acid), sample C synthesized from sample A (which is the product of direct C–H alkoxylation of *rac*-2-benzamidopropanoic acid under standard protocol)], and sample D synthesized from sample B (which is the product of direct C–H alkoxylation of D-2-benzamidopropanoic acid under standard protocol)] were separated by chiral HPLC using a Chiralcel-IC column (25% *i*-PrOH and 0.5%  $\text{CF}_3\text{COOH}$  in hexanes, flow rate 0.3 mL/min, UV lamp 215 or 254 nm). In the HPLC profile of sample A, the two peaks correspond to a 1:1 mixture of D-2-benzamidopropanoic acid ( $t_R = 17.3$  min) and L-2-benzamidopropanoic acid ( $t_R = 20.1$  min). In the HPLC profile of sample B, the peak corresponds to D-2-benzamidopropanoic acid ( $t_R = 17.3$  min). In the HPLC profile of sample C, the peak corresponds to a 1:1 mixture of D-2-(2-methoxybenzamido)propanoic acid ( $t_R = 39.1$  min) and L-2-(2-methoxybenzamido)propanoic acid ( $t_R = 48.6$  min). In the HPLC profile of sample D, the peak corresponds to D-2-(2-methoxybenzamido)propanoic acid, which indicates that no diastereomer of the product was observed.

**Analytical Characterization Data of Products.** 2-(2-Methoxybenzamido)-2-methylpropanoic Acid (**1a**). This compound is known.<sup>9a</sup>  $^1\text{H}$  NMR (400 MHz,  $\text{MeOD}-d_4$ )  $\delta$  8.46 (s, 1H), 7.82 (d,  $J = 7.2$  Hz, 2H), 7.55 (t,  $J = 7.3$  Hz, 1H), 7.46 (t,  $J = 7.7$  Hz, 2H), 1.61 (s, 6H).

1-Benzamidocyclopropane-1-carboxylic Acid (**1b**). This compound is known.<sup>9a</sup> Compound **1b** was prepared in a similar manner

as described for compound **1a**.  $^1\text{H}$  NMR (400 MHz,  $\text{DMSO}-d_6$ )  $\delta$  12.36 (s, 1H), 8.95 (s, 1H), 7.86–7.82 (m, 2H), 7.52 (d,  $J = 7.3$  Hz, 1H), 7.45 (t,  $J = 7.6$  Hz, 2H), 1.40 (dd,  $J = 7.7, 4.4$  Hz, 2H), 1.09 (dd,  $J = 7.7, 4.4$  Hz, 2H).

1-Benzamidocyclopentane-1-carboxylic Acid (**1c**). This compound is known.<sup>9b</sup> Compound **1c** was prepared in a similar manner as described for compound **1a**.  $^1\text{H}$  NMR (400 MHz,  $\text{DMSO}-d_6$ )  $\delta$  12.13 (s, 1H), 8.50 (s, 1H), 7.86–7.81 (m, 2H), 7.55–7.50 (m, 1H), 7.46 (t,  $J = 7.5$  Hz, 2H), 2.13 (m, 2H), 2.09–2.00 (m, 2H), 1.75–1.61 (m, 4H).

1-Benzamidocyclohexane-1-carboxylic Acid (**1d**). This compound is known.<sup>9c</sup> Compound **1d** was prepared in a similar manner as described for compound **1a**.  $^1\text{H}$  NMR (400 MHz,  $\text{DMSO}-d_6$ )  $\delta$  12.18 (s, 1H), 8.26 (s, 1H), 7.87 (d,  $J = 7.3$  Hz, 2H), 7.56 (d,  $J = 6.8$  Hz, 1H), 7.49 (t,  $J = 7.6$  Hz, 2H), 2.16 (m, 2H), 1.83–1.70 (m, 2H), 1.57 (m, 5H), 1.32 (m, 1H).

2-Benzamido-2-phenylacetic Acid (**1e**). This compound is known.<sup>9d</sup> Compound **1e** was prepared in a similar manner as described for compound **1a**.  $^1\text{H}$  NMR (400 MHz,  $\text{DMSO}-d_6$ )  $\delta$  12.93 (s, 1H), 9.06 (d,  $J = 7.4$  Hz, 1H), 7.93 (d,  $J = 7.5$  Hz, 2H), 7.50 (m, 5H), 7.37 (m, 3H), 5.61 (d,  $J = 7.4$  Hz, 1H).

Benzoylvaline (**1f**). This compound is known.<sup>9e</sup> Compound **1f** was prepared in a similar manner as described for compound **1a**.  $^1\text{H}$  NMR (400 MHz,  $\text{DMSO}-d_6$ )  $\delta$  12.60 (s, 1H), 8.42 (d,  $J = 8.2$  Hz, 1H), 7.88 (d,  $J = 7.6$  Hz, 2H), 7.54 (d,  $J = 7.3$  Hz, 1H), 7.47 (d,  $J = 7.3$  Hz, 2H), 4.28 (dd,  $J = 8.0, 6.0$  Hz, 1H), 2.19 (m, 1H), 0.97 (m, 6H).

2-Benzamidobutanoic Acid (**1g**). This compound is known.<sup>9e</sup> White compound **1g** was prepared in a similar manner as described for compound **1a**.  $^1\text{H}$  NMR (400 MHz,  $\text{DMSO}-d_6$ )  $\delta$  12.56 (s, 1H), 8.55 (d,  $J = 7.6$  Hz, 1H), 7.89 (d,  $J = 7.3$  Hz, 2H), 7.57–7.51 (m, 1H), 7.47 (m, 2H), 4.30 (ddd,  $J = 9.2, 7.8, 5.1$  Hz, 1H), 1.92–1.81 (m, 1H), 1.81–1.73 (m, 1H), 0.96 (t,  $J = 7.4$  Hz, 3H).

Benzoyl-L-alanine (**1h**). This compound is known.<sup>9e</sup> White compound **1h** was prepared in a similar manner as described for compound **1a**.  $^1\text{H}$  NMR (400 MHz,  $\text{DMSO}-d_6$ )  $\delta$  12.53 (s, 1H), 8.65 (d,  $J = 7.2$  Hz, 1H), 7.88 (d,  $J = 7.5$  Hz, 2H), 7.54 (d,  $J = 7.3$  Hz, 1H), 7.47 (m, 2H), 4.44–4.40 (m, 1H), 1.39 (d,  $J = 7.4$  Hz, 3H).

(*Benzoyl-2,3,4,5,6-d<sub>5</sub>*)alanine (**d<sub>5</sub>-1h**). <sup>1</sup>H NMR (400 MHz, MeOD-*d*<sub>4</sub>) δ 4.62 (q, *J* = 7.3 Hz, 1H), 1.54 (d, *J* = 7.3 Hz, 3H).

*Benzoylglycine* (**1i**). This compound is known.<sup>9e</sup> Compound **1i** was prepared in a similar manner as described for compound **1a**. <sup>1</sup>H NMR (400 MHz, MeOD-*d*<sub>4</sub>) δ 7.90–7.79 (d, *J* = 8.4 Hz, 2H), 7.52 (d, *J* = 7.4 Hz, 1H), 7.49–7.37 (m, 2H), 4.09 (s, 2H).

*2-Methyl-2-(4-methylbenzamido)propanoic Acid* (**1j**). This compound is known.<sup>9f</sup> Compound **1j** was prepared in a similar manner as described for compound **1a**. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 12.19 (s, 1H), 8.36 (s, 1H), 7.77 (d, *J* = 8.1 Hz, 2H), 7.26 (d, *J* = 8.0 Hz, 2H), 2.35 (s, 3H), 1.45 (s, 6H).

*2-(4-Methoxybenzamido)-2-methylpropanoic Acid* (**1k**). This compound is known.<sup>9f</sup> Compound **1k** was prepared in a similar manner as described for compound **1a**. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 12.12 (s, 1H), 8.28 (s, 1H), 7.83 (d, *J* = 8.8 Hz, 2H), 6.98 (d, *J* = 8.8 Hz, 2H), 3.80 (s, 3H), 1.43 (s, 6H).

*2-([1,1'-Biphenyl]-4-carboxamido)-2-methylpropanoic Acid* (**1l**). Compound **1l** was prepared in a similar manner as described for compound **1a**. White solid, 2.3 g, 56% yield. Mp: 156–158 °C. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 12.28 (s, 1H), 8.52 (s, 1H), 7.96 (d, *J* = 8.3 Hz, 2H), 7.77 (d, *J* = 8.2 Hz, 2H), 7.73 (d, *J* = 7.7 Hz, 2H), 7.49 (t, *J* = 7.5 Hz, 2H), 7.42 (d, *J* = 7.4 Hz, 1H), 1.47 (s, 6H). <sup>13</sup>C {<sup>1</sup>H} NMR (125 MHz, DMSO-*d*<sub>6</sub>) δ 176.0, 165.9, 143.1, 139.6, 129.5, 128.6, 127.3, 126.8, 55.9, 25.5. LRMS (ESI) [M – H]<sup>–</sup> *m/z* found: 282.0. HRMS (ESI-TOF) [M – H]<sup>–</sup> *m/z* calcd for C<sub>17</sub>H<sub>16</sub>NO<sub>3</sub>, 282.1136, found 282.1132.

*2-(4-Fluorobenzamido)-2-methylpropanoic Acid* (**1m**). Compound **1m** was prepared in a similar manner as described for compound **1a**. White solid, 1.6 g, 46% yield. Mp: 167–169 °C. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 12.22 (s, 1H), 8.49 (s, 1H), 7.93 (dd, *J* = 12.3, 5.3 Hz, 2H), 7.29 (dd, *J* = 12.3, 5.3 Hz, 2H), 1.45 (s, 6H). <sup>13</sup>C {<sup>1</sup>H} NMR (125 MHz, DMSO-*d*<sub>6</sub>) δ 176.0, 165.2, 165.1, 163.5, 131.2, 131.1, 130.7, 130.6, 115.5, 115.4, 55.9, 25.4. LRMS (ESI) [M – H]<sup>–</sup> *m/z* found: 224.0. HRMS (ESI-TOF) [M – H]<sup>–</sup> *m/z* calcd for C<sub>11</sub>H<sub>11</sub>FNO<sub>3</sub>, 224.0728, found 224.0724.

*2-(4-Chlorobenzamido)-2-methylpropanoic Acid* (**1n**). Compound **1n** was prepared in a similar manner as described for compound **1a**. White solid, 2.5 g, 56% yield. Mp: 185–187 °C. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 8.56 (s, 1H), 7.87 (d, *J* = 8.5 Hz, 2H), 7.53 (d, *J* = 8.5 Hz, 2H), 1.45 (s, 6H). <sup>13</sup>C {<sup>1</sup>H} NMR (125 MHz, DMSO-*d*<sub>6</sub>) δ 175.96, 165.31, 136.54, 133.41, 129.90, 128.71, 56.00, 25.40. LRMS (ESI) [M – H]<sup>–</sup> *m/z* found: 240.0. HRMS (ESI-TOF) [M – H]<sup>–</sup> *m/z* calcd for C<sub>11</sub>H<sub>11</sub>ClNO<sub>3</sub>, 240.0433, found 240.0429.

*2-(4-Bromobenzamido)-2-methylpropanoic Acid* (**1o**). Compound **1o** was prepared in a similar manner as described for compound **1a**. White solid, 1.3 g, 55% yield. Mp: 162–165 °C. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 12.23 (s, 1H), 8.55 (s, 1H), 7.80 (dd, *J* = 8.8, 2.0 Hz, 2H), 7.68 (dd, *J* = 8.8, 2.0 Hz, 2H), 1.45 (s, 6H). <sup>13</sup>C {<sup>1</sup>H} NMR (125 MHz, DMSO-*d*<sub>6</sub>) δ 175.9, 165.3, 133.7, 131.6, 130.1, 125.4, 55.9, 25.4. LRMS (ESI) [M – H]<sup>–</sup> *m/z* found: 283.9. HRMS (ESI-TOF) [M – H]<sup>–</sup> *m/z* calcd for C<sub>11</sub>H<sub>11</sub>BrNO<sub>3</sub>, 283.9928, found 283.9924.

*2-Methyl-2-(4-(trifluoromethyl)benzamido)propanoic Acid* (**1p**). Compound **1p** was prepared in a similar manner as described for compound **1a**. White solid, 3.1 g, 60% yield. Mp: 134–136 °C. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 12.30 (s, 1H), 8.73 (s, 1H), 8.05 (d, *J* = 8.1 Hz, 2H), 7.85 (d, *J* = 8.2 Hz, 2H), 1.47 (s, 6H). <sup>13</sup>C {<sup>1</sup>H} NMR (125 MHz, DMSO-*d*<sub>6</sub>) δ 175.8, 165.2, 138.5, 131.6, 131.4, 128.8, 125.7, 125.6, 125.3, 123.5, 56.1, 25.3. LRMS (ESI) [M – H]<sup>–</sup> *m/z* found: 274.0. HRMS (ESI-TOF) [M – H]<sup>–</sup> *m/z* calcd for C<sub>12</sub>H<sub>11</sub>F<sub>3</sub>NO<sub>3</sub>, 274.0697, found 274.0690.

*2-Methyl-2-(3-methylbenzamido)propanoic Acid* (**1q**). Compound **1q** was prepared in a similar manner as described for compound **1a**. White solid, 2.4 g, 44% yield. Mp: 165–167 °C. <sup>1</sup>H NMR (400 MHz, MeOD-*d*<sub>4</sub>) δ 7.67 (s, 1H), 7.62 (d, *J* = 6.9 Hz, 1H), 7.41–7.32 (m, 2H), 2.43 (s, 3H), 1.62 (s, 6H). <sup>13</sup>C {<sup>1</sup>H} NMR (125 MHz, DMSO-*d*<sub>6</sub>) δ 176.1, 166.1, 141.5, 131.9, 129.1, 127.9, 55.8, 25.5, 21.4. LRMS (ESI) [M – H]<sup>–</sup> *m/z* found: 220.0. HRMS (ESI-TOF) [M – H]<sup>–</sup> *m/z* calcd for C<sub>12</sub>H<sub>14</sub>NO<sub>3</sub>, 220.0979, found 220.0975.

*2-Methyl-2-(3-(trifluoromethyl)benzamido)propanoic Acid* (**1r**). Compound **1r** was prepared in a similar manner as described for

compound **1a**. White solid, 2.1 g, 34% yield. Mp: 145–147 °C. <sup>1</sup>H NMR (400 MHz, MeOD-*d*<sub>4</sub>) δ 8.71 (s, 1H), 8.11 (s, 1H), 8.05 (d, *J* = 7.8 Hz, 1H), 7.81 (d, *J* = 7.9 Hz, 1H), 7.64 (t, *J* = 7.8 Hz, 1H), 1.57 (s, 6H). <sup>13</sup>C {<sup>1</sup>H} NMR (125 MHz, DMSO-*d*<sub>6</sub>) δ 175.8, 164.8, 135.4, 132.1, 130.0, 129.5, 129.3, 128.3, 125.4, 124.5, 124.4, 123.5, 56.1, 25.3. LRMS (ESI) [M – H]<sup>–</sup> *m/z* found: 274.0. HRMS (ESI-TOF) [M – H]<sup>–</sup> *m/z* calcd for C<sub>12</sub>H<sub>11</sub>F<sub>3</sub>NO<sub>3</sub>, 274.0697, found 274.0693.

*2-Methyl-2-(thiophene-2-carboxamido)propanoic Acid* (**1s**). Compound **1s** was prepared in a similar manner as described for compound **1a**. White solid, 2.3 g, 56% yield. Mp: 134–136 °C. <sup>1</sup>H NMR (400 MHz, MeOD-*d*<sub>4</sub>) δ 8.40 (s, 1H), 7.76 (d, *J* = 3.7 Hz, 1H), 7.64 (d, *J* = 5.0 Hz, 1H), 7.12 (dd, *J* = 4.9, 3.8 Hz, 1H), 1.58 (s, 6H). <sup>13</sup>C {<sup>1</sup>H} NMR (125 MHz, DMSO-*d*<sub>6</sub>) δ 175.9, 161.1, 140.3, 131.3, 129.0, 128.3, 55.9, 25.5. LRMS (ESI) [M – H]<sup>–</sup> *m/z* found: 212.0. HRMS (ESI-TOF) [M – H]<sup>–</sup> *m/z* calcd for C<sub>9</sub>H<sub>10</sub>NO<sub>3</sub>S, 212.0387, found 212.0381.

*2-(2-Methoxybenzamido)-2-methylpropanoic Acid* (**2a**). This compound is known.<sup>9g</sup> White solid, 41 mg, 87% yield. Mp: 142–144 °C. <sup>1</sup>H NMR (400 MHz, MeOD-*d*<sub>4</sub>) δ 8.99 (s, 1H), 7.91 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.51–7.46 (m, 1H), 7.14 (dd, *J* = 8.3, 1.7 Hz, 1H), 7.04 (t, *J* = 8.1 Hz, 1H), 3.99 (s, 3H), 1.63 (s, 6H). <sup>13</sup>C {<sup>1</sup>H} NMR (125 MHz, MeOD-*d*<sub>4</sub>) δ 178.5, 167.3, 159.7, 134.8, 132.5, 123.3, 122.5, 113.5, 58.2, 57.1, 25.6. LRMS (ESI) [M – H]<sup>–</sup> *m/z* found: 236.0. LRMS (ESI) [M – H]<sup>–</sup> *m/z* found: 236.0. HRMS (ESI-TOF) [M – H]<sup>–</sup> *m/z* calcd for C<sub>12</sub>H<sub>14</sub>NO<sub>4</sub>, 236.0923, found 236.0919.

*1-(2-Methoxybenzamido)cyclopropane-1-carboxylic Acid* (**2b**). Compound **2b** was prepared in a similar manner as described for compound **2a**. White solid, 35 mg, 75% yield. Mp: 108–110 °C. <sup>1</sup>H NMR (400 MHz, MeOD-*d*<sub>4</sub>) δ 7.93–7.82 (m, 3H), 7.48 (dd, *J* = 8.8, 2.2 Hz, 1H), 7.16–7.11 (m, 1H), 7.04 (t, *J* = 7.5 Hz, 1H), 3.95 (s, 3H), 1.61–1.54 (m, 2H), 1.21–1.26 (m, 2H). <sup>13</sup>C {<sup>1</sup>H} NMR (125 MHz, MeOD-*d*<sub>4</sub>) δ 169.8, 159.7, 134.7, 132.6, 123.5, 122.3, 113.4, 57.0, 18.4. LRMS (ESI) [M – H]<sup>–</sup> *m/z* found: 234.0. HRMS (ESI-TOF) [M – H]<sup>–</sup> *m/z* calcd for C<sub>12</sub>H<sub>12</sub>NO<sub>4</sub>, 234.0766, found 234.0760.

*1-(2-Methoxybenzamido)cyclopentane-1-carboxylic Acid* (**2c**). Compound **2c** was prepared in a similar manner as described for compound **2a**. White solid, 38 mg, 73% yield. Mp: 106–108 °C. <sup>1</sup>H NMR (400 MHz, MeOD-*d*<sub>4</sub>) δ 7.87 (dd, *J* = 7.7, 1.6 Hz, 1H), 7.52–7.44 (m, 1H), 7.14 (d, *J* = 8.5 Hz, 1H), 7.05 (t, *J* = 7.5 Hz, 1H), 3.98 (s, 3H), 2.25–2.34 (m, 2H), 2.14–2.07 (m, 2H), 1.80–1.89 (m, 4H). <sup>13</sup>C {<sup>1</sup>H} NMR (125 MHz, MeOD-*d*<sub>4</sub>) δ 178.3, 167.9, 159.6, 134.7, 132.43, 123.4, 122.5, 113.5, 67.8, 57.1, 38.7, 26.2. LRMS (ESI) [M – H]<sup>–</sup> *m/z* found: 262.0. HRMS (ESI-TOF) [M – H]<sup>–</sup> *m/z* calcd for C<sub>14</sub>H<sub>16</sub>NO<sub>4</sub>, 262.1079, found 262.1073.

*1-(2-Methoxybenzamido)cyclohexane-1-carboxylic Acid* (**2d**). This compound is known.<sup>9d</sup> Compound **2d** was prepared in a similar manner as described for compound **2a**. White solid, 51 mg, 92% yield. Mp: 103–105 °C. <sup>1</sup>H NMR (400 MHz, MeOD-*d*<sub>4</sub>) δ 8.50 (s, 1H), 7.93–7.78 (m, 1H), 7.50 (ddd, *J* = 11.0, 8.9, 2.3 Hz, 1H), 7.17 (d, *J* = 8.6 Hz, 1H), 7.06 (t, *J* = 7.5 Hz, 1H), 4.02 (s, 3H), 2.13–2.24 (m, 2H), 1.81–1.90 (m, 2H), 1.64–1.76 (m, 4H), 1.47–1.61 (m, 2H). <sup>13</sup>C {<sup>1</sup>H} NMR (125 MHz, MeOD-*d*<sub>4</sub>) δ 182.3, 171.2, 163.6, 138.8, 136.5, 126.5, 119.3, 117.5, 64.5, 61.2, 37.7, 30.8, 27.1. LRMS (ESI) [M – H]<sup>–</sup> *m/z* found: 276.0. HRMS (ESI-TOF) [M – H]<sup>–</sup> *m/z* calcd for C<sub>15</sub>H<sub>18</sub>NO<sub>4</sub>, 276.1236, found 276.1228.

*2-(2-Methoxybenzamido)-2-phenylacetic Acid* (**2e**). Compound **2e** was prepared in a similar manner as described for compound **2a**. White solid, 42 mg, 73% yield. Mp: 173–175 °C. <sup>1</sup>H NMR (400 MHz, MeOD-*d*<sub>4</sub>) δ 7.97 (dd, *J* = 7.8, 1.6 Hz, 1H), 7.52–7.55 (m, 1H), 7.49–7.51 (m, 2H), 7.35 (t, *J* = 7.5 Hz, 2H), 7.30 (d, *J* = 7.2 Hz, 1H), 7.20 (d, *J* = 8.4 Hz, 1H), 7.06 (t, *J* = 7.5 Hz, 1H), 5.53 (s, 1H), 4.06 (s, 3H). <sup>13</sup>C {<sup>1</sup>H} NMR (125 MHz, MeOD-*d*<sub>4</sub>) δ 172.4, 164.6, 157.6, 137.7, 132.7, 130.4, 127.7, 127.0, 126.3, 120.2, 120.0, 111.2, 57.4, 54.0. LRMS (ESI) [M – H]<sup>–</sup> *m/z* found: 284.0. HRMS (ESI-TOF) [M – H]<sup>–</sup> *m/z* calcd for C<sub>16</sub>H<sub>14</sub>NO<sub>4</sub>, 284.0923, found 284.0915.

*(2-Methoxybenzoyl)valine* (**2f**). Compound **2f** was prepared in a similar manner as described for compound **2a**. White solid, 37 mg, 75% yield. Mp: 133–135 °C. <sup>1</sup>H NMR (400 MHz, MeOD-*d*<sub>4</sub>) δ 8.00–7.89 (m, 1H), 7.56–7.48 (m, 1H), 7.18 (d, *J* = 8.4 Hz, 1H), 7.08 (t, *J* = 7.6 Hz, 1H), 4.59 (d, *J* = 4.6 Hz, 1H), 4.02 (s, 3H), 2.38–2.23 (m, 1H), 1.03 (dd, *J* = 6.8, 1.4 Hz, 6H). <sup>13</sup>C {<sup>1</sup>H} NMR (125 MHz, MeOD-*d*<sub>4</sub>) δ 175.6,

167.9, 159.8, 135.0, 132.9, 122.7, 122.6, 113.6, 59.9, 57.3, 32.8, 20.1, 18.7. LRMS (ESI)  $[M - H]^-$   $m/z$  found: 250.0. HRMS (ESI-TOF)  $[M - H]^-$   $m/z$  calcd for  $C_{13}H_{16}NO_4$  250.1079 found 250.1075.

**2-(2-Methoxybenzamido)butanoic Acid (2g).** Compound **2g** was prepared in a similar manner as described for compound **2a**. White solid, 43 mg, 90% yield. Mp: 126–128 °C.  $^1H$  NMR (400 MHz, MeOD- $d_4$ )  $\delta$  8.00–7.88 (m, 1H), 7.52 (ddd,  $J = 8.9, 8.0, 2.3$  Hz, 1H), 7.19 (dd,  $J = 8.6, 3.2$  Hz, 1H), 7.08 (t,  $J = 7.6$  Hz, 1H), 4.67–4.51 (m, 1H), 4.02 (s, 3H), 2.09–1.97 (m, 1H), 1.83–1.94 (m, 1H), 1.00 (td,  $J = 7.4, 3.1$  Hz, 3H).  $^{13}C$   $\{^1H\}$  NMR (125 MHz, MeOD- $d_4$ )  $\delta$  176.0, 167.8, 159.8, 135.0, 132.7, 127.6, 122.5, 113.6, 57.2, 55.9, 26.7, 10.3. LRMS (ESI)  $[M - H]^-$   $m/z$  found: 236.0. HRMS (ESI-TOF)  $[M - H]^-$   $m/z$  calcd for  $C_{12}H_{14}NO_4$  236.0923, found 236.0924.

**(2-Methoxybenzoyl)-L-alanine (2h).** Compound **2h** was prepared in a similar manner as described for compound **2a**. White solid, 40 mg, 89% yield. Mp: 120–122 °C.  $^1H$  NMR (400 MHz, MeOD- $d_4$ )  $\delta$  8.00–7.88 (m, 1H), 7.51 (ddd,  $J = 10.2, 8.7, 2.3$  Hz, 1H), 7.17 (d,  $J = 8.2$  Hz, 1H), 7.07 (t,  $J = 7.6$  Hz, 1H), 4.68–4.52 (m, 1H), 4.01 (d,  $J = 1.7$  Hz, 3H), 1.52 (d,  $J = 7.1$  Hz, 3H).  $^{13}C$   $\{^1H\}$  NMR (125 MHz, MeOD- $d_4$ )  $\delta$  167.6, 159.9, 135.0, 132.7, 122.7, 122.5, 113.5, 57.1, 19.1. LRMS (ESI)  $[M - H]^-$   $m/z$  found: 222.0. HRMS (ESI-TOF)  $[M - H]^-$   $m/z$  calcd for  $C_{11}H_{12}NO_4$  222.0766, found 222.0760.

**(2-Methoxybenzoyl)glycine (2i).** This compound is known.<sup>91</sup> Compound **2i** was prepared in a similar manner as described for compound **2a**. White solid, 26 mg, 62% yield. Mp: 117–119 °C.  $^1H$  NMR (400 MHz, MeOD- $d_4$ )  $\delta$  8.00 (dd,  $J = 7.8, 1.8$  Hz, 1H), 7.51 (ddd,  $J = 8.4, 7.3, 1.9$  Hz, 1H), 7.14 (d,  $J = 8.4$  Hz, 1H), 7.06 (d,  $J = 8.2$  Hz, 1H), 4.14 (s, 2H), 3.99 (s, 3H).  $^{13}C$   $\{^1H\}$  NMR (101 MHz, MeOD- $d_4$ )  $\delta$  173.6, 168.3, 159.9, 135.0, 132.8, 122.4, 113.4, 57.0, 43.1. LRMS (ESI)  $[M - H]^-$   $m/z$  found: 208.0. HRMS (ESI-TOF)  $[M - H]^-$   $m/z$  calcd for  $C_{10}H_{10}NO_4$  208.0610, found 208.0607.

**2-(2-Methoxy-4-methylbenzamido)-2-methylpropanoic Acid (2j).** Compound **2j** was prepared in a similar manner as described for compound **2a**. White solid, 34 mg, 67% yield. Mp: 98–100 °C.  $^1H$  NMR (400 MHz, MeOD- $d_4$ )  $\delta$  8.90 (s, 1H), 7.84 (d,  $J = 7.9$  Hz, 1H), 6.98 (s, 1H), 6.89 (d,  $J = 8.0$  Hz, 1H), 4.00 (s, 3H), 2.40 (s, 3H), 1.65 (s, 6H).  $^{13}C$   $\{^1H\}$  NMR (150 MHz, MeOD- $d_4$ )  $\delta$  165.3, 157.8, 144.1, 130.7, 121.4, 118.5, 114.4, 112.2, 61.2, 55.1, 23.7, 20.3. LRMS (ESI)  $[M - H]^-$   $m/z$  found: 250.0. HRMS (ESI-TOF)  $[M - H]^-$   $m/z$  calcd for  $C_{13}H_{16}NO_4$  250.1079, found 250.1029.

**2-(2,4-Dimethoxybenzamido)-2-methylpropanoic Acid (2k).** Compound **2k** was prepared in a similar manner as described for compound **2a**. White solid, 38 mg, 72% yield. Mp: 112–114 °C.  $^1H$  NMR (400 MHz, MeOD- $d_4$ )  $\delta$  7.91 (d,  $J = 8.9, 1H$ ), 6.63 (m, 2H), 3.99 (s, 3H), 3.85 (s, 3H), 1.64 (s, 6H).  $^{13}C$   $\{^1H\}$  NMR (100 MHz, MeOD- $d_4$ )  $\delta$  178.6, 166.9, 165.9, 161.2, 134.3, 115.6, 107.3, 99.9, 57.12, 56.5, 25.7. LRMS (ESI)  $[M - H]^-$   $m/z$  found: 266.0. HRMS (ESI-TOF)  $[M - H]^-$   $m/z$  calcd for  $C_{13}H_{16}NO_5$  266.1028, found 266.1024.

**2-(3-Methoxy-[1,1'-biphenyl]-4-carboxamido)-2-methylpropanoic Acid (2l).** Compound **2l** was prepared in a similar manner as described for compound **2a**. White solid, 34 mg, 55% yield. Mp: 156–158 °C.  $^1H$  NMR (400 MHz, MeOD- $d_4$ )  $\delta$  9.01 (s, 1H), 8.01 (d,  $J = 8.1$  Hz, 1H), 7.68 (dd,  $J = 8.3, 1.3$  Hz, 2H), 7.48–7.44 (m, 2H), 7.39 (d,  $J = 7.4$  Hz, 1H), 7.34 (d,  $J = 1.5$  Hz, 1H), 7.32 (dd,  $J = 8.1, 1.6$  Hz, 1H), 4.08 (s, 3H), 1.66 (s, 6H).  $^{13}C$   $\{^1H\}$  NMR (100 MHz, MeOD- $d_4$ )  $\delta$  166.9, 160.07, 148.0, 141.7, 133.2, 130.5, 129.7, 128.7, 122.1, 122.0, 121.0, 111.9, 58.5, 57.2, 25.6. LRMS (ESI)  $[M - H]^-$   $m/z$  found: 312.0. HRMS (ESI-TOF)  $[M - H]^-$   $m/z$  calcd for  $C_{18}H_{18}NO_4$  312.1236, found 312.1234.

**2-(4-Fluoro-2-methoxybenzamido)-2-methylpropanoic Acid (2m).** Compound **2m** was prepared in a similar manner as described for compound **2a**. White solid, 33 mg, 64% yield. Mp: 86–88 °C.  $^1H$  NMR (400 MHz, MeOD- $d_4$ )  $\delta$  8.81 (s, 1H), 7.97 (dd,  $J = 8.6, 7.1$  Hz, 1H), 6.97 (dd,  $J = 11.0, 2.3$  Hz, 1H), 6.82 (td,  $J = 8.3, 2.3$  Hz, 1H), 4.02 (s, 3H), 1.65 (s, 6H).  $^{13}C$   $\{^1H\}$  NMR (125 MHz, MeOD- $d_4$ )  $\delta$  174.7, 163.5, 157.3, 130.6, 115.9, 105.1, 97.5, 54.3, 53.6, 21.6. LRMS (ESI)  $[M - H]^-$   $m/z$  found: 254.0. HRMS (ESI-TOF)  $[M - H]^-$   $m/z$  calcd for  $C_{12}H_{13}NO_4F$  254.0829, found 254.0829.

**2-(4-Chloro-2-methoxybenzamido)-2-methylpropanoic Acid (2n).** Compound **2n** was prepared in a similar manner as described

for compound **2a**. White solid, 30 mg, 55% yield. Mp: 112–114 °C.  $^1H$  NMR (400 MHz, MeOD- $d_4$ )  $\delta$  8.91 (s, 1H), 7.90 (d,  $J = 8.4$  Hz, 1H), 7.21 (d,  $J = 1.8$  Hz, 1H), 7.09 (dd,  $J = 8.4, 1.8$  Hz, 1H), 4.03 (s, 3H), 1.65 (s, 6H).  $^{13}C$   $\{^1H\}$  NMR (125 MHz, MeOD- $d_4$ )  $\delta$  165.0, 159.0, 138.9, 132.6, 121.4, 121.3, 112.9, 56.4, 24.3. LRMS (ESI)  $[M - H]^-$   $m/z$  found: 270.0. HRMS (ESI-TOF)  $[M - H]^-$   $m/z$  calcd for  $C_{12}H_{13}NO_4Cl$  270.0533, found 270.0531.

**2-(4-Bromo-2-methoxybenzamido)-2-methylpropanoic Acid (2o).** Compound **2o** was prepared in a similar manner as described for compound **2a**. White solid, 39 mg, 62% yield. Mp: 116–118 °C.  $^1H$  NMR (400 MHz, MeOD- $d_4$ )  $\delta$  8.90 (s, 1H), 7.81 (d,  $J = 8.4$  Hz, 1H), 7.33 (s, 1H), 7.23 (dd,  $J = 8.3, 1.4$  Hz, 1H), 4.02 (s, 3H), 1.65 (s, 6H).  $^{13}C$   $\{^1H\}$  NMR (100 MHz, MeOD- $d_4$ )  $\delta$  166.3, 160.0, 133.9, 128.3, 125.7, 122.8, 117.0, 58.6, 57.6, 25.5. LRMS (ESI)  $[M - H]^-$   $m/z$  found: 314.0. HRMS (ESI-TOF)  $[M - H]^-$   $m/z$  calcd for  $C_{12}H_{13}BrNO_4$  314.0028, found 314.0019, 316.003.

**2-(2-Methoxy-4-(trifluoromethyl)benzamido)-2-methylpropanoic Acid (2p).** Compound **2p** was prepared in a similar manner as described for compound **2a**. White solid, 35 mg, 57% yield. Mp: 160–162 °C.  $^1H$  NMR (400 MHz, MeOD- $d_4$ )  $\delta$  8.99 (s, 1H), 8.03 (d,  $J = 8.0$  Hz, 1H), 7.40 (s, 1H), 7.37 (d,  $J = 8.3$  Hz, 1H), 4.07 (s, 3H), 1.66 (s, 6H).  $^{13}C$   $\{^1H\}$  NMR (125 MHz, MeOD- $d_4$ )  $\delta$  177.7, 164.9, 158.4, 134.52, 132.0, 126.6, 124.2, 117.7, 109.23, 57.5, 56.4, 24.3. LRMS (ESI)  $[M - H]^-$   $m/z$  found: 304.0. HRMS (ESI-TOF)  $[M - H]^-$   $m/z$  calcd for  $C_{13}H_{13}NO_4F_3$  304.0797, found 304.0793.

**2-(2-Methoxy-5-methylbenzamido)-2-methylpropanoic Acid (2q).** Compound **2q** was prepared in a similar manner as described for compound **2a**. White solid, 44 mg, 88% yield. Mp: 142–144 °C.  $^1H$  NMR (400 MHz, MeOD- $d_4$ )  $\delta$  8.93 (s, 1H), 7.75 (d,  $J = 2.0$  Hz, 1H), 7.31 (dd,  $J = 8.4, 2.2$  Hz, 1H), 7.04 (d,  $J = 8.4$  Hz, 1H), 3.98 (s, 3H), 1.65 (s, 6H).  $^{13}C$   $\{^1H\}$  NMR (125 MHz, MeOD- $d_4$ )  $\delta$  178.8, 167.31, 157.6, 135.1, 132.7, 131.9, 122.8, 113.5, 58.3, 57.1, 25.6, 20.9. LRMS (ESI)  $[M - H]^-$   $m/z$  found: 250.0. HRMS (ESI-TOF)  $[M - H]^-$   $m/z$  calcd for  $C_{13}H_{16}NO_4$  250.1079, found 250.1074.

**2-(2-Methoxy-5-(trifluoromethyl)benzamido)-2-methylpropanoic Acid (2r).** Compound **2r** was prepared in a similar manner as described for compound **2a**. White solid, 37 mg, 60% yield. Mp: 177–179 °C.  $^1H$  NMR (400 MHz, MeOD- $d_4$ )  $\delta$  8.19 (d,  $J = 2.1$  Hz, 1H), 7.81 (dd,  $J = 8.7, 2.1$  Hz, 1H), 7.34 (d,  $J = 8.7$  Hz, 1H), 4.09 (s, 3H), 1.66 (s, 6H).  $^{13}C$   $\{^1H\}$  NMR (125 MHz, MeOD- $d_4$ )  $\delta$  178.6, 165.8, 162.0, 131.4, 129.4, 126.1, 124.4, 124.4, 114.2, 58.5, 57.6, 25.5. LRMS (ESI)  $[M - H]^-$   $m/z$  found: 304.0. HRMS (ESI-TOF)  $[M - H]^-$   $m/z$  calcd for  $C_{13}H_{13}NO_4F_3$  304.0797, found 304.0790.

**2-(3-Methoxythiophene-2-carboxamido)-2-methylpropanoic Acid (2s).** Compound **2s** was prepared in a similar manner as described for compound **2a**. White solid, 24 mg, 49% yield. Mp: 137–139 °C.  $^1H$  NMR (400 MHz, MeOD- $d_4$ )  $\delta$  8.13 (s, 2H), 7.61 (d,  $J = 5.5$  Hz, 1H), 7.08 (d,  $J = 5.5$  Hz, 1H), 4.08 (s, 3H), 1.65 (s, 6H).  $^{13}C$   $\{^1H\}$  NMR (125 MHz, MeOD- $d_4$ )  $\delta$  178.5, 163.6, 159.4, 131.1, 117.6, 117.2, 60.3, 58.1, 25.7. LRMS (ESI)  $[M - H]^-$   $m/z$  found: 242.0. HRMS (ESI-TOF)  $[M - H]^-$   $m/z$  calcd for  $C_{10}H_{12}NO_4S$  242.0487, found 242.0482.

**2-(2-Ethoxybenzamido)-2-methylpropanoic Acid (3a).** Compound **3a** was prepared in a similar manner as described for compound **2a**. White solid, 49 mg, 95% yield. Mp: 137–139 °C.  $^1H$  NMR (400 MHz, MeOD- $d_4$ )  $\delta$  9.02 (s, 1H), 7.96 (d,  $J = 7.7$  Hz, 1H), 7.50 (t,  $J = 7.5$  Hz, 2H), 7.14 (d,  $J = 8.4$  Hz, 1H), 7.06 (t,  $J = 7.6$  Hz, 1H), 4.26 (q,  $J = 6.9$  Hz, 2H), 1.66 (s, 6H), 1.56 (t,  $J = 7.0$  Hz, 3H).  $^{13}C$   $\{^1H\}$  NMR (125 MHz, MeOD- $d_4$ )  $\delta$  167.2, 159.1, 134.7, 132.5, 123.2, 122.4, 114.40, 66.6, 25.7, 15.6. LRMS (ESI)  $[M - H]^-$   $m/z$  found: 250.0. HRMS (ESI-TOF)  $[M - H]^-$   $m/z$  calcd for  $C_{13}H_{16}NO_4$  250.1079, found 250.1078.

**2-Methyl-2-(2-propoxybenzamido)propanoic Acid (3b).** Compound **3b** was prepared in a similar manner as described for compound **2a**. White solid, 50 mg, 94% yield. Mp: 167–169 °C.  $^1H$  NMR (400 MHz, MeOD- $d_4$ )  $\delta$  8.86 (s, 1H), 7.92 (dd,  $J = 7.8, 1.7$  Hz, 1H), 7.55–7.33 (m, 1H), 7.12 (d,  $J = 8.3$  Hz, 1H), 7.03 (t,  $J = 7.6$  Hz, 1H), 4.13 (t,  $J = 6.4$  Hz, 2H), 1.99–1.88 (m, 2H), 1.63 (s, 6H), 1.10 (t,  $J = 7.4$  Hz, 3H).  $^{13}C$   $\{^1H\}$  NMR (125 MHz, MeOD- $d_4$ )  $\delta$  178.5, 167.3, 159.1, 134.8, 132.5, 123.2, 122.3, 114.3, 72.5, 58.2, 25.9, 24.0, 11.6. LRMS (ESI)  $[M - H]^-$   $m/z$  found: 264.0. HRMS (ESI-TOF)  $[M - H]^-$   $m/z$  calcd for  $C_{14}H_{18}NO_4$  264.1236, found 264.1240.

**2-Methyl-2-(2-(3,3,3-trifluoropropoxy)benzamido)propanoic Acid (3c).** Compound 3c was prepared in a similar manner as described for compound 2a. White solid, 53 mg, 83% yield. Mp: 175–177 °C. <sup>1</sup>H NMR (400 MHz, MeOD-*d*<sub>4</sub>) δ 8.74 (s, 1H), 7.91 (dd, *J* = 7.8, 1.4 Hz, 1H), 7.56–7.43 (m, 1H), 7.15 (d, *J* = 8.3 Hz, 1H), 7.09 (t, *J* = 7.6 Hz, 1H), 4.41 (t, *J* = 5.9 Hz, 2H), 2.96–2.80 (m, 1H), 1.64 (s, 6H). <sup>13</sup>C {<sup>1</sup>H} NMR (125 MHz, MeOD-*d*<sub>4</sub>) δ 178.8, 167.0, 158.1, 134.7, 132.7, 123.9, 123.0, 114.0, 63.9, 58.5, 34.9, 25.4. LRMS (ESI) [M – H]<sup>–</sup> *m/z* found: 318.0. HRMS (ESI-TOF) [M – H]<sup>–</sup> *m/z* calcd for C<sub>14</sub>H<sub>15</sub>NO<sub>4</sub>F<sub>3</sub> 318.0953, found 318.0945.

**2-Methyl-2-(2-phenethoxybenzamido)propanoic Acid (3d).** Compound 3d was prepared in a similar manner as described for compound 2a. White solid, 50 mg, 76% yield. Mp: 183–185 °C. <sup>1</sup>H NMR (400 MHz, MeOD-*d*<sub>4</sub>) δ 8.73 (s, 1H), 7.93 (d, *J* = 7.7 Hz, 1H), 7.50 (t, *J* = 7.0 Hz, 1H), 7.38–7.27 (m, 4H), 7.26–7.21 (m, 1H), 7.19 (d, *J* = 8.5 Hz, 1H), 7.07 (t, *J* = 7.6 Hz, 1H), 4.48 (t, *J* = 6.7 Hz, 2H), 3.27 (t, *J* = 6.7 Hz, 2H), 1.51 (s, 6H). <sup>13</sup>C {<sup>1</sup>H} NMR (125 MHz, MeOD-*d*<sub>4</sub>) δ 167.1, 158.7, 139.7, 134.7, 132.7, 130.3, 130.3, 130.1, 128.1, 123.4, 122.5, 114.4, 70.9, 36.5, 25.6. LRMS (ESI) [M – H]<sup>–</sup> *m/z* found: 326.0. HRMS (ESI-TOF) [M – H]<sup>–</sup> *m/z* calcd for C<sub>19</sub>H<sub>20</sub>NO<sub>4</sub> 326.1392, found 326.1393.

**2-(2-(Benzoyloxy)benzamido)-2-methylpropanoic Acid (3e).** Compound 3e was prepared in a similar manner as described for compound 2a. White solid, 29 mg, 46% yield. Mp: 178–180 °C. <sup>1</sup>H NMR (400 MHz, MeOD-*d*<sub>4</sub>) δ 8.67 (s, 1H), 7.95 (d, *J* = 7.7 Hz, 1H), 7.58 (d, *J* = 7.1 Hz, 2H), 7.47–7.54 (m, 1H), 7.40–7.49 (m, 2H), 7.38–7.44 (m, 1H), 7.28 (d, *J* = 8.3 Hz, 1H), 7.10 (t, *J* = 7.6 Hz, 1H), 5.27 (s, 2H), 1.38 (s, 6H). <sup>13</sup>C {<sup>1</sup>H} NMR (125 MHz, MeOD-*d*<sub>4</sub>) δ 167.2, 158.9, 137.9, 134.7, 132.6, 130.3, 130.1, 130.1, 123.6, 122.7, 114.9, 73.0, 25.8. LRMS (ESI) [M – H]<sup>–</sup> *m/z* found: 312.0. HRMS (ESI-TOF) [M – H]<sup>–</sup> *m/z* calcd for C<sub>18</sub>H<sub>18</sub>NO<sub>4</sub> 312.1236, found 312.1230.

**2-(2-Isobutoxybenzamido)-2-methylpropanoic Acid (3f).** Compound 3f was prepared in a similar manner as described for compound 2a. White solid, 40 mg, 72% yield. Mp: 143–145 °C. <sup>1</sup>H NMR (400 MHz, MeOD-*d*<sub>4</sub>) δ 8.77 (s, 1H), 7.92 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.54–7.44 (m, 1H), 7.14 (d, *J* = 8.4 Hz, 1H), 7.06 (t, *J* = 7.5 Hz, 1H), 3.97 (d, *J* = 6.5 Hz, 2H), 2.18–2.30 (m, 1H), 1.65 (s, 6H), 1.11 (d, *J* = 6.1 Hz, 6H). <sup>13</sup>C {<sup>1</sup>H} NMR (125 MHz, MeOD-*d*<sub>4</sub>) δ 178.4, 167.5, 159.1, 134.7, 132.5, 123.3, 122.3, 114.2, 77.2, 58.1, 29.9, 25.9, 20.2. LRMS (ESI) [M – H]<sup>–</sup> *m/z* found: 278.0. HRMS (ESI-TOF) [M – H]<sup>–</sup> *m/z* calcd for C<sub>15</sub>H<sub>20</sub>NO<sub>4</sub> 278.1392, found 278.1385.

**2-(2-Isopropoxybenzamido)-2-methylpropanoic Acid (3g).** Compound 3g was prepared in a similar manner as described for compound 2a. White solid, 26 mg, 49% yield. Mp: 137–139 °C. <sup>1</sup>H NMR (400 MHz, MeOD-*d*<sub>4</sub>) δ 9.00 (s, 1H), 7.94 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.51–7.38 (m, 1H), 7.15 (d, *J* = 8.4 Hz, 1H), 7.03 (t, *J* = 7.6 Hz, 1H), 4.82–4.91 (m, 1H), 1.64 (s, 6H), 1.44 (d, *J* = 6.1 Hz, 6H). <sup>13</sup>C {<sup>1</sup>H} NMR (125 MHz, MeOD-*d*<sub>4</sub>) δ 176.5, 165.5, 165.4, 156.1, 132.7, 130.8, 122.3, 120.6, 114.3, 72.1, 23.8, 20.9. LRMS (ESI) [M – H]<sup>–</sup> *m/z* found: 264.0. HRMS (ESI-TOF) [M – H]<sup>–</sup> *m/z* calcd for C<sub>14</sub>H<sub>18</sub>NO<sub>4</sub> 264.1236, found 264.1229.

**2-(2-(Cyclopropylmethoxy)benzamido)-2-methylpropanoic Acid (3h).** Compound 3h was prepared in a similar manner as described for compound 2a. White solid, 19 mg, 35% yield. Mp: 146–148 °C. <sup>1</sup>H NMR (400 MHz, MeOD-*d*<sub>4</sub>) δ 9.05 (s, 2H), 7.97 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.51–7.43 (m, 1H), 7.13–6.99 (m, 2H), 4.03 (d, *J* = 7.2 Hz, 2H), 1.65 (s, 6H), 1.37–1.47 (m, 1H), 0.73–0.66 (m, 2H), 0.43–0.56 (m, 2H). <sup>13</sup>C {<sup>1</sup>H} NMR (125 MHz, MeOD-*d*<sub>4</sub>) δ 178.5, 167.2, 159.2, 134.9, 132.6, 122.9, 122.4, 114.5, 75.8, 58.0, 26.0, 11.5, 4.3. LRMS (ESI) [M – H]<sup>–</sup> *m/z* found: 276.0. HRMS (ESI-TOF) [M – H]<sup>–</sup> *m/z* calcd for C<sub>15</sub>H<sub>18</sub>NO<sub>4</sub> 276.1236, found 276.1231.

**2-(2-(Cyclohexyloxy)benzamido)-2-methylpropanoic Acid (3i).** Compound 3i was prepared in a similar manner as described for compound 2a. White solid, 31 mg, 50% yield. Mp: 150–152 °C. <sup>1</sup>H NMR (400 MHz, MeOD-*d*<sub>4</sub>) δ 8.96 (s, 1H), 7.94–7.88 (dd, *J* = 8.4, 1.2, 1H), 7.45 (t, *J* = 7.8 Hz, 1H), 7.16 (d, *J* = 8.3 Hz, 1H), 7.02 (t, *J* = 7.5 Hz, 1H), 4.59–4.49 (m, 1H), 2.04–2.14 (m, 2H), 1.79–1.89 (m, 2H), 1.62–1.68 (m, 8H), 1.50–1.43 (m, 2H), 1.42–1.32 (m, 2H). <sup>13</sup>C {<sup>1</sup>H} NMR (100 MHz, MeOD-*d*<sub>4</sub>) δ 167.5, 157.7, 134.4, 132.7, 124.6, 122.3, 116.0, 79.1, 33.4, 27.0, 25.8, 25.4. LRMS (ESI) [M – H]<sup>–</sup> *m/z* found:

304.0. HRMS (ESI-TOF) [M – H]<sup>–</sup> *m/z* calcd for C<sub>17</sub>H<sub>22</sub>NO<sub>4</sub> 304.1549, found 304.1545.

## ■ ASSOCIATED CONTENT

### Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.joc.6b02257.

Copies of <sup>1</sup>H and <sup>13</sup>C {<sup>1</sup>H} NMR spectra and HPLC experiments data (PDF)

## ■ AUTHOR INFORMATION

### Corresponding Author

\*E-mail: hliu@simc.ac.cn.

### Notes

The authors declare no competing financial interest.

## ■ ACKNOWLEDGMENTS

S.L., W.Z., F.G., J.W., and H.L. received funding from the National Natural Science Foundation of China (81220108025, 21472209, and 91229204), the Major Project of Chinese National Programs for Fundamental Research and Development (2015CB910304), the National Basic Research Program of China (2012CB518005), and National S&T Major Projects (2013ZX09507-001 and 2014ZX09507002-001).

## ■ REFERENCES

- (1) For selected papers, see: (a) Majmudar, J. D.; Hodges-Loaiza, H. B.; Hahne, K.; Donelson, J. L.; Song, J.; Shrestha, L.; Harrison, M. L.; Hrycyna, C. A.; Gibbs, R. A. *Bioorg. Med. Chem.* **2012**, *20*, 283–295. (b) Roughley, S. D.; Jordan, A. M. *J. Med. Chem.* **2011**, *54*, 3451–3479. (c) Takeuchi, Y.; Ozaki, S.; Satoh, M.; Mimura, K.; Hara, S.; Abe, H.; Nishioka, H.; Harayama, T. *Chem. Pharm. Bull.* **2010**, *58*, 1552–1553. (d) Wang, S.; Beck, R.; Blench, T.; Burd, A.; Buxton, S.; Malic, M.; Ayele, T.; Shaikh, S.; Chahwala, S.; Chander, C.; Holland, R.; Merette, S.; Zhao, L.; Blackney, M.; Watts, A. *J. Med. Chem.* **2010**, *53*, 1465–1472.
- (2) (a) Imramovsky, A.; Jorda, R.; Pauk, K.; Reznickova, E.; Dusek, J.; Hanusek, J.; Krystof, V. *Eur. J. Med. Chem.* **2013**, *68*, 253–259. (b) Yang, B.; Lamb, M. L.; Zhang, T.; Hennessy, E. J.; Grewal, G.; Sha, L.; Zambrowski, M.; Block, M. H.; Dowling, J. E.; Su, N.; Wu, J.; Deegan, T.; Mikule, K.; Wang, W.; Kaspera, R.; Chuaqui, C.; Chen, H. *J. Med. Chem.* **2014**, *57*, 9958–9970.
- (3) (a) Maier, T. C.; Fu, G. C. *J. Am. Chem. Soc.* **2006**, *128*, 4594–4595. (b) Shintou, T.; Mukaiyama, T. *J. Am. Chem. Soc.* **2004**, *126*, 7359–7367. (c) Vo, C. V.; Mitchell, T. A.; Bode, J. W. *J. Am. Chem. Soc.* **2011**, *133*, 14082–14089.
- (4) (a) Ackermann, L. *Chem. Rev.* **2011**, *111*, 1315–1345. (b) Engle, K. M.; Mei, T. S.; Wasa, M.; Yu, J. Q. *Acc. Chem. Res.* **2012**, *45*, 788–802. (c) Peron, F.; Fossey, C.; Sopkova-de Oliveira Santos, J.; Cailly, T.; Fabis, F. *Chem. - Eur. J.* **2014**, *20*, 7507–7513. (d) Bag, S.; Patra, T.; Modak, A.; Deb, A.; Maity, S.; Dutta, U.; Dey, A.; Kancharla, R.; Maji, A.; Hazra, A.; Bera, M.; Maiti, D. *J. Am. Chem. Soc.* **2015**, *137*, 11888–11891. (e) Bera, M.; Maji, A.; Sahoo, S. K.; Maiti, D. *Angew. Chem., Int. Ed.* **2015**, *54*, 8515–8519. (f) Kolle, S.; Batra, S. *Org. Biomol. Chem.* **2015**, *13*, 10376–10385. (g) Maji, A.; Bhaskararao, B.; Singha, S.; Sunoj, R. B.; Maiti, D. *Chem. Sci.* **2016**, *7*, 3147–3153. (h) Bera, M.; Sahoo, S. K.; Maiti, D. *ACS Catal.* **2016**, *6*, 3575–3579.
- (5) (a) Castro, L. C. M.; Chatani, N. *Chem. - Eur. J.* **2014**, *20*, 4548–4553. (b) Gong, W.; Zhang, G.; Liu, T.; Giri, R.; Yu, J. Q. *J. Am. Chem. Soc.* **2014**, *136*, 16940–16946. (c) Kim, J.; Sim, M.; Kim, N.; Hong, S. *Chem. Sci.* **2015**, *6*, 3611–3616. (d) Toba, T.; Hu, Y.; Tran, A. T.; Yu, J. Q. *Org. Lett.* **2015**, *17*, 5966–5969.
- (6) (a) Dick, A. R.; Hull, K. L.; Sanford, M. S. *J. Am. Chem. Soc.* **2004**, *126*, 2300–2301. (b) Gao, T.; Sun, P. *J. Org. Chem.* **2014**, *79*, 9888–9893. (c) Jiang, T. S.; Wang, G. W. *J. Org. Chem.* **2012**, *77*, 9504–9509. (d) Shi, S.; Kuang, C. *J. Org. Chem.* **2014**, *79*, 6105–6112. (e) Siciliano,



C.; Barattucci, A.; Bonaccorsi, P.; Di Gioia, M. L.; Leggio, A.; Minuti, L.; Romio, E.; Temperini, A. *J. Org. Chem.* **2014**, *79*, 5320–5326. (f) Yin, Z.; Jiang, X.; Sun, P. *J. Org. Chem.* **2013**, *78*, 10002–10007. (g) Zhang, C.; Sun, P. *J. Org. Chem.* **2014**, *79*, 8457–8461. (h) Zhang, L. B.; Hao, X. Q.; Zhang, S. K.; Liu, K.; Ren, B.; Gong, J. F.; Niu, J. L.; Song, M. P. *J. Org. Chem.* **2014**, *79*, 10399–10409.

(7) (a) Chen, F.-J.; Zhao, S.; Hu, F.; Chen, K.; Zhang, Q.; Zhang, S.-Q.; Shi, B.-F. *Chem. Sci.* **2013**, *4*, 4187–4192. (b) Zhang, S. Y.; He, G.; Zhao, Y.; Wright, K.; Nack, W. A.; Chen, G. *J. Am. Chem. Soc.* **2012**, *134*, 7313–7316.

(8) (a) Li, H.; Li, P.; Wang, L. *Org. Lett.* **2013**, *15*, 620–623. (b) Lian, B.; Zhang, L.; Chass, G. A.; Fang, D. C. *J. Org. Chem.* **2013**, *78*, 8376–8385.

(9) (a) Lucchesi, C.; Arbore, A.; Pascual, S.; Fontaine, L.; Maignan, C.; Dujardin, G. *Carbohydr. Res.* **2010**, *345*, 844–849. (b) Satyanarayana, B.; Sumalatha, Y.; Sridhar, C.; Venkatraman, S.; Reddy, P. P. *Heterocycl. Commun.* **2006**, *12*, 323–328. (c) Saavedra, C.; Hernandez, R.; Boto, A.; Alvarez, E. *J. Org. Chem.* **2009**, *74*, 4655–4665. (d) Sofia; Chakravarty; Katzenellenbogen. *J. Org. Chem.* **1983**, *48*, 3318–3325. (e) Saavedra, C.; Hernandez, R.; Boto, A.; Alvarez, E. *J. Org. Chem.* **2009**, *74*, 4655–4665. (f) Reinaud; Capdevielle; Maumy. *Synthesis* **1990**, *7*, 612–614. (g) Buijs, W.; Comba, P.; Corneli, D.; Pritzkow, H. *J. Organomet. Chem.* **2002**, *641*, 71–80. (h) Schaefer, G.; Bode, J. W. *Org. Lett.* **2014**, *16*, 1526–1529. (i) Su, W.; Chen, J.; Jin, C. *Heterocycles* **2011**, *83*, 153–161.